AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 222 min read$ICU

SeaStar Medical Holding Corporation (ICU) Reports Statistically Significant Survival Benefit in QUELIMMUNE SAVE Analysis

SeaStar Medical reported that its QUELIMMUNE (SCD-PED) treatment showed statistically significant higher survival rates at Day 60, Day 90, and hospital discharge in pediatric sepsis-associated AKI requiring CRRT, with no device-related adverse events observed, according to the company.

Original reporting
tradingview.com
Published Oct 22, 2026, 4:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 4:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
SeaStar Medical Holding Corporation (ICU) Reports Statistically Significant Survival Benefit in QUELIMMUNE SAVE Analysis — source image
Source · tradingview.com
Decision brief

The 30-second read

$ICUBullishMed
01

Why it matters

The new survival data could accelerate adoption and payer coverage, influencing revenue forecasts.

02

Market read

First disclosure of significant clinical outcomes for a pediatric renal device, likely to affect stock valuation.

03

What to watch

Regulatory pathway and reimbursement decisions could moderate the impact.

Relevance 8/10Novelty 8/10Timing: immediate

Background

SeaStar Medical Holding Corp (ICU) focuses on renal replacement therapies; QUELIMMUNE is its pediatric device.

Company-level read

Ticker impact

$ICUBullishHigh confidence
Context

SeaStar Medical reported statistically significant survival benefit for its QUELIMMUNE device in pediatric sepsis AKI patients.

Expected impact

upward pressure as market prices in the survival benefit.

Evidence & confidence

First report of significant trial results for a niche device; no prior data disclosed.

Market effects

Sector

May improve outlook for pediatric renal support devices and related biotech sector.

Regional

Potential uplift for US-based medical device stocks.

Global

Limited to niche market but could attract international interest in pediatric therapies.

Counterpoint

What could challenge this read

Skeptics may question the size of the study and real-world applicability.

Key entities

  • company
    SeaStar Medical Holding Corp

    Developer of QUELIMMUNE device.

Read at source← All news

StorySeaStar Medical reports higher 90‑day survival for pediatric sepsis‑AKI patients using QUELIMMUNE

Also covered by

1 outlet

Related articles

OCT 7
$ICUHighAI 8/10

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

SeaStar Medical (ICU) received FDA Breakthrough Device Designation for its SCD therapy to treat hyperinflammation in adult sepsis patients. This designation accelerates development and review. Sepsis affects 1.7M U.S. adults annually, with high mortality rates. The company plans to submit data to the FDA soon. This is the seventh such designation for the SCD therapy across various indications.

globenewswire.com2 min
OCT 1
$ICUMed

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

SeaStar Medical (ICU) announced new ICD-10-PCS codes for its SCD therapy in treating acute kidney injury (AKI). The codes streamline hospital billing and expand access to QUELIMMUNE therapy. The company expects this to support broader adoption and potential future indications. QUELIMMUNE showed a 77% survival rate in clinical trials, with no dialysis required for survivors.

globenewswire.com2 min